American International Group’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

American International Group’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-16,793	Closed	-$1.8M	–	3242
2023 Q1	$1.8M	Buy	16,793 +334	+2%	+$38.4K	0.01%	981
2022 Q4	$1.81M	Buy	16,459 +1,925	+13%	+$125K	0.01%	976
2022 Q3	$858K	Buy	14,534 +836	+6%	+$38.3K	0.01%	1268
2022 Q2	$387K	Sell	13,698 -1,182	-8%	-$34.3K	﹤0.01%	1781
2022 Q1	$562K	Sell	14,880 -1,048	-7%	-$41.4K	﹤0.01%	1660
2021 Q4	$630K	Buy	15,928 +9,742	+157%	+$305K	﹤0.01%	1672
2021 Q3	$147K	Sell	6,186 -147	-2%	-$3.47K	﹤0.01%	2609
2021 Q2	$156	Buy	+6,333	New	+$141K	﹤0.01%	2662

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

American International Group's RXDX Position: Q2 2023 in Review

American International Group sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 16,793 shares — an estimated $1.8M sold.

American International Group first reported a position in RXDX in Q2 2021 and held it in 8 quarters. The position peaked at $1.81M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

American International Group reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
American International Group sold 16,793 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $1.8M.
American International Group first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
American International Group's Prometheus Biosciences, Inc. Common Stock position peaked at $1.81M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on American International Group's 13F filing for Q2 2023, filed 4 Aug 2023.